Obiltoxaximab Drugbank ID :DB05336 Molecular Weight (Daltons) :148000 Description : Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

Indication : Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. Pharmacodynamics : NA Mechanism of action : ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

Metabolism :NA Absorption : Mean Cmax and AUCinf were 400 ± 91.2 mcg/mL and 5170 ± 1360 mcg•day/mL, respectively. Volume of distribution :NA Clearance :NA Categories : NA Patents : NA Brands : Anthim Company : Elusys Therapeutics, Inc. Formulation : Solution Form : Liquid Route of administration : Intravenous infusion

Dosage : The recommended dosage of ANTHIM in adult patients is a single dose of 16 mg/kg administered intravenously over 90 minutes (1 hour and 30 minutes); For adult patients weighing less than 40 kg. Contraindication : NA Side effects : Hypersensitivity and Anaphylaxis

Useful links http://www.rxlist.com/anthim-drug/side-effects-interactions.htm